Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Short-term Investments (2016 - 2025)

Vanda Pharmaceuticals' Short-term Investments history spans 16 years, with the latest figure at $179.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 34.27% year-over-year to $179.0 million; the TTM value through Dec 2025 reached $179.0 million, down 34.27%, while the annual FY2025 figure was $179.0 million, 34.27% down from the prior year.
  • Short-term Investments for Q4 2025 was $179.0 million at Vanda Pharmaceuticals, down from $223.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $405.4 million in Q3 2022 and bottomed at $147.3 million in Q1 2023.
  • The 5-year median for Short-term Investments is $295.4 million (2021), against an average of $294.7 million.
  • The largest annual shift saw Short-term Investments tumbled 59.99% in 2023 before it surged 82.58% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $380.7 million in 2021, then decreased by 12.85% to $331.8 million in 2022, then decreased by 23.92% to $252.4 million in 2023, then rose by 7.88% to $272.3 million in 2024, then tumbled by 34.27% to $179.0 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Short-term Investments are $179.0 million (Q4 2025), $223.7 million (Q3 2025), and $244.6 million (Q2 2025).